Rezultati pretraživanja
  1. prije 9 sati

    wow what a great surprise 4.02 %

  2. 4. velj

    Short sale volume (not short interest) for on 2020-02-03 is 31%. 41% 35% 35%

  3. 4. velj
  4. 4. velj

    : New Insider Filing on Chairman, President and CEO TIMOTHY P WALBERT:

  5. 4. velj

    Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020

  6. 4. velj
  7. 4. velj

    Short sale volume (not short interest) for at 2020-02-03 is 47%. 40% 62% 56% 31%

  8. 2. velj

    Brokerages Expect Horizon Therapeutics PLC to Announce $0.43 EPS

  9. 1. velj

    BMO 10 key other catalysts in 2020 (OP): Uptake from Tepezza launch with J-code 10/1/20; 2) (OP): Potential approvals/launches of JZP-258 and Lurbinectedin in 2H20; 3) (OP): Potential approvals of Apomorphine in May and Libervant in 2H20; 4) (OP): closing

    Prikaži ovu nit
  10. In report published today, Ken Cacciatore previewed select specialty pharmaceutical company earnings, including , , , , , , and

  11. 30. sij

    Zacks: Brokerages Expect Horizon Therapeutics PLC Will Announce Earnings of $0.43 Per Share

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.